Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00440726
Recruitment Status : Completed
First Posted : February 27, 2007
Results First Posted : February 19, 2020
Last Update Posted : February 19, 2020
Sponsor:
Information provided by (Responsible Party):
Therapeutic Advances in Childhood Leukemia Consortium

Tracking Information
First Submitted Date  ICMJE February 23, 2007
First Posted Date  ICMJE February 27, 2007
Results First Submitted Date  ICMJE October 2, 2018
Results First Posted Date  ICMJE February 19, 2020
Last Update Posted Date February 19, 2020
Actual Study Start Date  ICMJE August 4, 2006
Actual Primary Completion Date February 26, 2011   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 7, 2020)
  • Occurrence of a Dose-Limiting Toxicity (Phase 1) [ Time Frame: Beginning with the first dose of investigational product until 30 days following the last dose of bortezomib ]
    Toxicity will be graded using the CTCAE criteria, version 3.0. Dose-limiting toxicity will be defined as any of the following events that are deemed by the investigator as possibly, probably or definitely attributable to bortezomib: Grade 3 or 4 Sensory Neuropathy; Grade 3 or 4 Neuropathic pain (Neuralgia or peripheral nerve) lasting longer than 24 hours despite medical intervention; Marrow hypoplasia, which continues 6 weeks from the start of each course (less than 10% cellularity); and Grade 4 Non-Hematologic Toxicity excluding the following: Infection (septic shock, typhlitis), Fever/Neutropenia, Fatigue, Electrolyte abnormalities, Hyper/Hypoglycemia, Nausea or Vomiting, AST/ALT/Bilirubin elevations that return to grade 1 by the time of the next course.
  • Achievement of Complete Remission (CR) [ Time Frame: Day 29 of Course 1 ]
    • Complete Remission (CR): M1 (< 5% blasts) BM with no evidence of circulating blasts or extramedullary disease and with recovery of peripheral counts (ANC>750/uL and platelet count >75 000/uL);
    • Complete Remission without Platelet Recovery (CRp): M1 BM with no circulating blasts or extramedullary disease and recovery of ANC (>750/uL) but insufficient recovery of platelets (<75 000/uL).
    • Partial Remission (PR): the disappearance of circulating blasts and achievement of M2 (5%-25% blasts) marrow status, without new sites of extramedullary disease, and with recovery of ANC (>750/uL).
    • Stable disease (SD): not satisfying the criterion for progressive disease (PD), or a recovery of ANC (>750/uL) but fails to qualify for CR, CRp, or PR.
    • Progressive Disease (PD): increase of at least 25% in the absolute number of circulating leukemia cells, development of new sites of extramedullary disease, or other lab or clinical evidence of PD, with or without recovery of ANC or platelets.
Original Primary Outcome Measures  ICMJE
 (submitted: February 26, 2007)
  • Dose limiting toxicity
  • Maximum tolerated dose
  • Rate of remission
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE
 (submitted: February 26, 2007)
Disease free survival
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
Official Title  ICMJE A Study of Bortezomib With Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
Brief Summary This is a Phase I/II study of a drug called bortezomib given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) for treating adults with multiple myeloma which is a type of blood cancer. Bortezomib has been shown to cause cancer cells to die in studies done on animals (mice). Studies have been done that have shown that some adults and children with cancer have shown a response to bortezomib when it is used alone. Studies have also been done in adults to evaluate the dose of bortezomib that can be safely given in combination with other chemotherapy drugs.
Detailed Description

All patients will receive 1 course of chemotherapy unless medical complications prevent the administration of some of the drugs. Treatment will last about 1 month.

Treatment on this study will consist of a combination of 7 anti-cancer medications. The 7 anti-cancer medicines are bortezomib, vincristine, dexamethasone, PEG-asparaginase, doxorubicin, cytarabine (Ara-C), and methotrexate (MTX).

If you are in the Phase I portion of this study, you will be given an assigned dose of bortezomib. The dose of bortezomib will be based on doses given in previous studies done with adults and children. At each dose level of bortezomib, between 3 and 6 children will receive bortezomib in combination with chemotherapy. If the side effects are not too severe, the next group of children will receive a higher dose. The dose will continue to be increased until we find the dose that causes serious side effects. Your dose of bortezomib will not be increased. If you have bad side effects, your dose may be decreased.

The dose used during the Phase 2 part of this study will be determined by the outcome of the Phase I study. The highest dose used in Phase I that was tolerated without serious side effects will be the one used in Phase 2.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Acute Lymphoblastic Leukemia
Intervention  ICMJE
  • Drug: Bortezomib
    Intravenous on days 1, 4, 8 and 11. Dose assigned at study entry.
    Other Name: Velcade
  • Drug: Dexamethasone
    10 mg/m2/day divided BID, oral administration for 14 days.
    Other Name: Decadron
  • Drug: PEG-asparaginase
    2500 IU/m2/day, intramuscular injection on Days 2, 8, 15 and 22
    Other Name: Oncaspar
  • Drug: Doxorubicin
    60 mg/m2/day IV over 15 minutes on Day 1
    Other Names:
    • Adriamycin
    • Rubex
  • Drug: Cytarabine

    Given intrathecally on Day 1 of course 1 at the dose defined by age below.

    • 30 mg for patients age 1-1.99
    • 50 mg for patients age 2-2.99
    • 70 mg for patients >3 years of age
    Other Names:
    • Cytosar-U
    • Ara-C
    • Arabinosylcytosine
  • Drug: Methotrexate

    Given intrathecally to all patients who are CNS 1 at study entry on Day 15 at the dose defined by age below.

    • 8 mg for patients age 1-1.99
    • 10 mg for patients age 2-2.99
    • 12 mg for patients 3-8.99 years of age
    • 15 mg for patients >9 years of age
    Other Names:
    • Otrexup
    • Rasuvo
    • Rheumatrex
    • Trexall
    • Amethopterin
  • Drug: Vincristine
    1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22.
    Other Names:
    • Oncovin
    • Leurocristine
  • Drug: Triple IT Therapy

    Triple IT therapy will be given intrathecally on Day 8, 15, and 22 for patients who are CNS 2 and CNS 3 at study entry. Regimen/dosing as follows:

    Methotrexate-

    • <2 years: 8 mg
    • 2 - <3 y: 10 mg
    • 3 - <9 y: 12 mg
    • >=9 y: 15 mg

    Cytarabine:

    • <2 years: 16 mg
    • 2 - <3 y: 20 mg
    • 3 - <9 y: 24 mg
    • >=9 y: 30 mg

    Hydrocortisone:

    • <2 years: 8 mg
    • 2 - <3 y: 10 mg
    • 3 - <9 y: 12 mg
    • >=9 y: 15 mg
Study Arms  ICMJE
  • Experimental: Ph 1 Dose Escalation
    Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. 3+3 escalation design.
    Interventions:
    • Drug: Bortezomib
    • Drug: Dexamethasone
    • Drug: PEG-asparaginase
    • Drug: Doxorubicin
    • Drug: Cytarabine
    • Drug: Methotrexate
    • Drug: Vincristine
    • Drug: Triple IT Therapy
  • Experimental: Ph 2 Efficacy and Safety
    Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. Patients receive bortezomib at maximum tolerated dose (as established in the Phase 1 portion of the study) and are assessed for response and toxicity.
    Interventions:
    • Drug: Bortezomib
    • Drug: Dexamethasone
    • Drug: PEG-asparaginase
    • Drug: Doxorubicin
    • Drug: Cytarabine
    • Drug: Methotrexate
    • Drug: Vincristine
    • Drug: Triple IT Therapy
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 18, 2012)
31
Original Enrollment  ICMJE
 (submitted: February 26, 2007)
35
Actual Study Completion Date  ICMJE February 26, 2011
Actual Primary Completion Date February 26, 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

The eligibility criteria listed below are interpreted literally and cannot be waived.

  1. Age Patients must be < 21 years of age when originally diagnosed with ALL. Patient must be > 1 year of age at study entry.
  2. Diagnosis Patients must have relapsed or refractory ALL with a M3 marrow (marrow blasts >25%). Patients with CNS I, II or III or testicular disease are eligible.
  3. Performance Level Karnofsky > 50% for patients > 10 years of age and Lansky > 50% for patients < 10 years of age.
  4. Prior Therapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

    1. Prior anthracycline exposure: Patients must have less than 400mg/m2 lifetime exposure of anthracycline chemotherapy.
    2. Stem Cell Transplant (SCT): Patients are eligible after allogeneic stem cell transplant as long as patients are not actively being treated for graft-versus-host-disease (GvHD).
    3. Patients should not have received previous therapy using bortezomib (Velcdade® or PS-341).
    4. During the phase I portion of the trial, there is no limit on the number of prior treatment regimens. Patients with persistent disease after an induction attempt are eligible.
    5. During the phase II portion of the trial, patients must have had two or more prior therapeutic attempts defined as:

      • Persistent initial disease after two induction attempts, or
      • Relapse after one-reinduction attempt (2nd relapse), or
      • Persistent disease after first relapse and initial re-induction attempt

      (Patients in first relapse are not eligible for the phase II portion of the study)

    6. During the phase II portion of the trial, patients must have no more than 3 prior therapeutic attempts and it must be at least 3 months since the last treatment with a "VPLD" induction/re-induction regimen.
  5. Reproductive Function

    1. Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.
    2. Female patients with infants must agree not to breastfeed their infants while on this study.
    3. Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study.

Exclusion Criteria

  1. Drug Allergies

    Patients will be excluded if they have allergies to the following:

    • Asparaginase products
    • Boron
    • Mannitol
  2. Renal Function Patients will be excluded if their serum creatinine is > 2 x the upper limit of normal for age at the institution's laboratory.
  3. Liver/Pancreatic Function

    1. Direct bilirubin > 1.5x the institutional ULN for age. A total bilirubin result that is less than 1.5 times the institutional ULN for age may be used for eligibility if a direct bilirubin result is not available.
    2. SGPT (ALT) > 4 x institutional ULN
    3. Grade 3 or greater pancreatitis as defined by the CTCAE v3.0
    4. History of any L-asparaginase induced pancreatitis
    5. Amylase or Lipase > 2 x institutional ULN
  4. Cardiac Function Patients will be excluded if their shortening fraction by echocardiogram is less than 30%.
  5. Patients with Down Syndrome are excluded.
  6. Infection

    • Patients will be excluded if they have an active uncontrolled infection.
    • Patients will be excluded if they have had a positive culture within 2 weeks of study entry.
  7. Patients with grade 2 or greater motor or sensory neuropathy per CTC 3.0 criteria.
  8. Patients planning on receiving other investigational agents while on this study. (An investigational agent is defined as any drug not currently approved for use in humans.)
  9. Patients planning on receiving other anti-cancer therapies while on this study. Hydroxyurea for cyto-reduction is allowed prior to the start of therapy.
  10. Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
  11. Patients who have started protocol therapy prior to enrollment. Patient may still enroll if IT therapy was given within 72 hours of study enrollment as part of the diagnostic lumbar procedure.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 1 Year to 21 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Brazil,   Canada,   United States
Removed Location Countries Korea, Republic of
 
Administrative Information
NCT Number  ICMJE NCT00440726
Other Study ID Numbers  ICMJE T2005-003
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Therapeutic Advances in Childhood Leukemia Consortium
Study Sponsor  ICMJE Therapeutic Advances in Childhood Leukemia Consortium
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Yoav Messinger, MD Children's Hospital and Clinics of Minnesota
PRS Account Therapeutic Advances in Childhood Leukemia Consortium
Verification Date February 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP